{"id":"W3004714210","doi":"10.1111/bjh.16462","title":"Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"AOP Orphan; Incyte; Baxalta; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; Alexion Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Teva Pharmaceutical Industries; Gilead Sciences; Sanofi; Bristol-Myers Squibb","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Discontinuation; Internal medicine; Cohort; Adverse effect; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00533472,0.0010805,0.002211657,0.0005623017,0.000613068,0.0009998208,0.000536375,0.000731394,0.005295815],"category_scores_gemma":[0.003201004,0.0003929939,0.002789473,0.0005336468,0.0004336065,0.0006809692,0.0007077947,0.001306781,0.0007844162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005344113,"about_ca_system_score_gemma":0.001220628,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000704999,"about_ca_topic_score_gemma":0.00265892,"domain_scores_codex":[0.9980737,0.0007753248,0.0001606274,0.0004069517,0.0004094615,0.0001739428],"domain_scores_gemma":[0.9960129,0.001350569,0.001114418,0.0003842878,0.0006060656,0.0005317362],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.701011,0.005012203,0.1833294,0.005511578,0.01776815,0.0006725816,0.0002988603,0.002024315,0.02269159,0.0006371948,0.01969082,0.04135227],"study_design_scores_gemma":[0.1430058,0.1084755,0.6939149,0.0003331223,0.02377257,0.001300399,0.0001906797,0.004152238,0.005563556,0.001103509,0.01802639,0.0001612688],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9763668,0.004063291,0.0009559669,0.0003572508,0.000109796,0.002240701,0.01223255,0.0001106888,0.003562964],"genre_scores_gemma":[0.974059,0.0007505064,0.00115272,0.0006764011,0.0003239412,0.002984834,0.01747349,0.00004368421,0.00253536],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00533472,"threshold_uncertainty_score":0.02821302,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04091387740162374,"score_gpt":0.3584157042767382,"score_spread":0.3175018268751145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}